Tag Archives: UK

The British Medical Journal's Statin 'Apology'

By Philip Ward. For any Brit involved in medical publishing, the British Medical Journal (BMJ) is the Holy Grail. So it came as a huge shock when editor-in-chief Fiona Godlee, MD, admitted last week that important — and seemingly quite basic — mistakes were made in a key paper on statins. Worse still, she didn’t […]
Posted in Europe, Guest Blog, healthcare, Medical Education, Op-Ed | Also tagged , , , , | Leave a comment

The United Kingdom: Rx for America's Pharma Tax Blues?

by Tom Norton The dizzying flurry of press releases from both Pfizer Inc. and AstraZeneca over a possible PFE acquisition of AZN have Rx experts on both sides of the Atlantic buzzing… From the US side, the most frequent thing that I have heard over the last 48 hours is, “You have got to be […]
Posted in Corporate Responsibility, Deals, Europe, FDA, Global, Guest Blog, leadership, Legal, People, Strategy | Also tagged , , , , , , , | 1 Comment

Pfizer’s AZ Bid Draws Mixed UK Reaction

The confirmation of Pfizer’s bid for an outright acquisition of AstraZeneca has drawn mixed reactions from the UK. Linda McCulloch of Britain’s biggest union, Unite, said the bid is “very worrying for the UK workforce”, adding that it is “absolutely crucial” that there should be “guarantees of no jobs losses and for the protection on the UK’s […]
Posted in Deals, Europe, Global, Supply Chain | Also tagged , , | Leave a comment

Pursuing the 'Real' Cost Effectiveness Threshold in England

By Leela Barham. The Incremental Cost Effectiveness Ratio (ICER) thresholds used by agencies such as the UK’s National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), and as far afield as Australia by the Pharmaceutical Benefits Advisory Committee (PBAC) are often controversial. This is mostly because it means analysts saying that a […]
Posted in Europe, Guest Blog, Op-Ed, pricing | Also tagged , , , , , , , , , | Leave a comment

Pricing and Reimbursement in Europe: Where Does Innovation Fit?

By Leela Barham. It was recently said, in reference to the UK’s Value-Based Assessment(VBA) program, that innovation had not been “tried and tested in the pricing context”, which explains the loss of the “innovation” criteria from the proposals formerly known as Value-Based Pricing (VBP). This prompted me to think about just how has innovation been […]
Posted in Europe, Global, Guest Blog, pricing, R&D | Also tagged , , , , | Leave a comment
  • Categories

  • Meta